Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

The primary purpose of this study is to test the safety and tolerability of the
administration of a single dose of jCell to adults with retinitis pigmentosa.

The goal of jCell therapy is to preserve vision by intervening in the disease at a time when
host photoreceptors can be protected and potentially reactivated.

Human allogeneic retinal progenitor cells will be injected into adults with advanced RP to
see if the procedure is safe, if the cells survive, and whether they have any impact on the
visual status of the patients.

Inclusion Criteria:

- Clinical diagnosis of RP confirmed by electroretinogram (ERG) and willing to consent
to mutation typing, if not already done

- Best corrected visual acuity (BCVA) 20/63 or worse and no worse than hand motions (HM)

- Adequate organ function and negative infectious disease screen

- Female of childbearing potential must have negative pregnancy test and be willing to
use medically accepted methods of contraception throughout the study

Exclusion Criteria:

- Eye disease other than RP that impairs visual function

- Pseudo-RP, cancer-associated retinopathies

- History of malignancy or other end-stage organ disease, or any chronic disease
requiring continuous treatment with system steroids, anticoagulants or
immunosuppressive agents

- Known allergy to penicillin or streptomycin